Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children

Acute Lung Injury Clinical Trial

— TRALI  

Official title:

Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02613377
• Other study ID #: CHUSJ-MP-21-2016-1070
• Status: Completed
• Start date: January 2016
• Est. completion date: December 2021

Study information

• Verified date: April 2023
• Source: St. Justine's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Transfusions cause more adverse events in children than in adults. Patients in pediatric intensive care units (PICU) are particularly exposed to transfusions of plasma-rich blood products (red blood cell (RBC), plasma and platelets) and the risk of adverse events after a transfusion is particularly high in this vulnerable population. Transfusion-related acute lung injury (TRALI), an acute inflammation of the lungs that impairs gas exchange leading to acute respiratory failure, is one of the 2 most deadly transfusion complications in the general population. There is limited evidence on TRALI incidence and impact in critically ill children. This reduces the awareness of PICU team for this complication, and makes the decision process to transfuse particularly difficult. Moreover, acute lung injury is highly prevalent in critically ill children. It is therefore complex to ascertain if the high frequency of respiratory deteriorations observed after a transfusion in PICU is explained by the transfusion itself or by the evolution of the patient's critical illness.

The investigators will conduct a cohort study of consecutive transfused critically ill children, with a control group of matched non-transfused children. The primary objective is to determine if transfusion of RBC, plasma and/or platelets in PICU is an independent risk factor of TRALI, and to compare the respiratory evolution in the two matched (transfused and non-transfused) groups. The secondary objectives will include the determination of the incidence rate, risk factors and clinical impact of TRALI in transfused PICU patients. The investigators will study both "classic TRALI" and "delayed TRALI".

Description:

Study Design This prospective cohort study will include all consecutive transfused patients admitted to the participating PICUs over a one-year period and a control group of matched non-transfused patients. The primary objectives will be assessed using the complete cohort of transfused and non-transfused patients. Secondary objectives will be studied in transfused patients.

Outcomes The primary outcome measure is TRALI (definite, probable, and delayed TRALI) as defined in section. In the non-transfused patients, the definition of Acute Lung Injury will be the same as the one used as a criterion for defining TRALI, and the observation period will be a similar 72-h period, starting at the same time zero.

Primary Objectives

• Objective #1a: to determine if the transfusion of RBC, plasma or platelets is an independent risk factor of TRALI in critically ill children.

• Objective #1b: to compare the progression of the respiratory function, in particular the SpO2/FiO2 ratio, in transfused and non-transfused PICU patients.

Secondary Objectives

• Objective #2.a : To determine the incidence rate of classic (definite or probable) TRALI and of delayed TRALI in transfused PICU patients.

• Objective #2.b : To characterize the risk factors of classic (definite or probable) TRALI and of delayed TRALI in transfused PICU patients.

• Objective #2.c : To compare the progression of respiratory parameters after a 1st transfusion in PICU patients with classic TRALI, delayed TRALI, and without TRALI.

• Objective #2.d : To compare the outcomes of transfused PICU patients with and without classic (definite or probable) TRALI and delayed TRALI.

• Objective #2.e : To describe the inflammatory profile of PICU patients with definite, probable, and delayed TRALI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 717
• Est. completion date: December 2021
• Est. primary completion date: January 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Days to 18 Years

Eligibility

Inclusion Criteria:

• admission to the PICU

Exclusion Criteria:

• gestational age < 40 weeks at entry into PICU

• post-term age less than 3 days or more than 18 years at PICU admission

• patients on extra-corporeal membrane oxygenation or ventricular assist device

• pregnancy present at entry into the PICU

• admission to PICU just after labor

Related Conditions & MeSH terms

• Acute Lung Injury
• Lung Injury
• Transfusion-Related Acute Lung Injury
• Wounds and Injuries

Intervention

Other:
• Blood transfusion

Locations

Country	Name	City	State
Canada	Alberta Children's Hospital	Calgary	Alberta
Canada	Montreal Children's Hospital	Montreal	Quebec
Canada	St. Justine's Hospital	Montreal	Quebec
Canada	Children's Hospital of Eastern Ontario	Ottawa	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
St. Justine's Hospital	Canadian Blood Services

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transfusion-related acute lung injury		72 hours
Secondary	Length of PICU stay (days)		28 days
Secondary	28-day all cause mortality		28 days
Secondary	Multiple organ dysfunction syndrome (MODS)		28 days